Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab (Q46985480)
Jump to navigation
Jump to search
scientific article published on 8 October 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab |
scientific article published on 8 October 2013 |
Statements
Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab (English)
Fabio Da Roit
Luca Bologna
Claudia Ferrara
Alessandro Rambaldi
Christian Klein
8 October 2013
122
20
3482-3491